Ford, John A., Elders, Andrew, Shyangdan, Deepson S., Royle, Pamela and Waugh, Norman. (2012) The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema : an indirect comparison in a systematic review. BMJ, Vol.345 . e5182. ISSN 0959-535X

Preview

Text WRAP_Waugh_clinical_effectiveness_ranibizumab.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (528Kb) | Preview

Abstract

Objective To indirectly compare the effectiveness of ranibizumab and bevacizumab in the treatment of diabetic macular oedema. Design Systematic review and indirect comparison. Data sources Medline (1996–September 2011), Embase (1996–September 2011), and the Cochrane Central Register of Controlled Trials (Issue 4, 2011). Selection criteria for studies Randomised trials evaluating ranibizumab or bevacizumab in diabetic macular oedema with a common comparator and sufficient methodological similarity to be included within an indirect comparison were eligible for inclusion. Main outcome measures The primary outcome was the proportion of patients with an improvement in best corrected visual acuity of more than two lines on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. Secondary outcomes included mean changes in best corrected visual acuity and in central macular thickness, and adverse events. Best corrected visual acuity was converted to logMAR units, a linear scale of visual acuity with positive values representing increasing visual loss. Indirect comparisons were done using Bayesian methods to estimate relative treatment effects of bevacizumab and ranibizumab. Results Five randomised controlled trials with follow-up of 6–12 months and a common comparator (multiple laser treatment) were sufficiently similar to be included in the indirect comparison. Generally studies were small, resulting in wide credible intervals. The proportions of patients with an improvement in best corrected visual acuity of >2 lines were 21/77 participants (27%) for bevacizumab and 60/152 participants (39%) for ranibizumab (odds ratio 0.95 (95% credible interval 0.23 to 4.32)). The wide credible intervals cannot exclude a greater improvement, or worse outcome, for either drug. The mean change in best corrected visual acuity non-significantly favoured bevacizumab (treatment effect −0.08 logMAR units (−0.19 to 0.04)). The difference in mean change in central macular thickness was not statistically significant between ranibizumab and bevacizumab (treatment effect −6.9 μm (−88.5 to 65.4)). Conclusions Results suggest no difference in effectiveness between bevacizumab and ranibizumab, but the wide credible intervals cannot exclude the possibility that either drug might be superior. Sufficiently powered, direct head to head trials are needed.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Edema -- Treatment, Diabetic retinopathy -- Treatment, Bevacizumab
Journal or Publication Title:	BMJ
Publisher:	BMJ Publishing Group Ltd.
ISSN:	0959-535X
Date:	13 August 2012
Volume:	Vol.345
Page Range:	e5182
Identification Number:	10.1136/bmj.e5182
Status:	Not Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
Related URLs:	Related dataset
References:	1 Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond) 2004;18:963-83. 2 Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-55. 3 Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796-806. 4 Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long term visual results. Ophthalmology 1991;98:1594-604 5 Simo R, Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008;51:1574-80. 6 Parravano M, Oddone F, Tedeschi M, Schiano LD, Chiaravalloti A, Ripandelli G, et al. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab. Retina 2009;29:329-34. 7 Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2010;249:15-27. 8 Yilmaz T, Cordero-Coma M, Gallagher MJ, Teasley LA. Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Acta Ophthalmol 2011;89:709-17. 9 McCartney M. Off-label prescribing in macular degeneration. BMJ 201:343:d6778. 10 Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-6. 11 National Institute for Health and Clinical Excellence. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: NICE technology appraisal guidance 155. 2008. http://guidance.nice.org.uk/TA155. 12 Medical University of Vienna. Bevacizumab versus ranibizumab for diabetic retinopathy. 2007. http://clinicaltrials.gov/ct2/show/NCT00545870?term=NCT00545870&rank=1. 13 National Institute for Health and Clinical Excellence. Ranibizumab for the treatment of diabetic macular oedema. NICE technology appraisal guidance TA237. 2011. http:// guidance.nice.org.uk/TA237. 14 National Institute for Health and Clinical Excellence. Ranibizumab for the treatment of diabetic macular oedema; appeal decision. NICE technology appraisal guidance TZ237. 2011. www.nice.org.uk/nicemedia/live/13125/57323/57323.pdf. 15 Liberati A, Altman DG, Tetzlaff J, Mulrow C, Goetzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100. 16 Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS—a Bayesian modelling framework: concepts, structure, and extensibility. Stat Computing 2000;10:325-37. 17 Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24. 18 Dias S, Welton NJ, Sutton AJ. Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011. www.nicedsu.org.uk. 19 Song F, Loke Y, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:b1147. 20 Michaelides M, Fraser-Bell S, Hamilton R, Kaines A, Egan C, Bunce C, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt study): report 1. Retina 2010;30:781-6. 21 Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-86. 22 Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007;27:1187-95. 23 Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142-50. 24 Soheilian M, Ramezani A, Yaseri M, Mirdehghan SA, Obudi A, Bijanzadeh B. Initial macular thickness and response to treatment in diabetic macular edema. Retina 2011;31:1564-73. 25 Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25. 26 Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009;116:2175-81. 27 Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2010;117:2146-51. 28 Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77. 29 Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL III, Friedman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-14. 30 Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114:743-50. 31 Googe J, Brucker AJ, Bressler NM, Qin H, Aiello LP, Antoszyk A, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011;31:1009-27. 32 Kohly RP, Muni RH, Kertes PJ. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular EDEMA. Evidence-Based Ophthalmology 2010;11:199-201. 33 Seo JW, Park IW. Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J Ophthalmol 2009;23:17-22. 34 Sheth S, Rush R, Natarajan S, Gillies M. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema. Clin Experimental Ophthalmol 2011;39:673-81. 35 Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina 2010;30:1638-45. 36 Wang Y-S, Li X, Wang H-Y, Zhang Z-F, Li M-H, Su X-N. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema. Chin Med J 2011;124:352-8. 37 Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M,et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Experimental Ophthalmol 2008;246:483-9. 38 Cheema RA, Al-Mubarak MM, Amin YM, Cheema MA. Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study. J Cataract Refractive Surg 2009;35:18-25. 39 Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK,et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-7. 40 Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A,et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008;18:941-8. 41 Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S,et al. Efficacy of 1.25 mg versus 2.5 mg intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 2009;29:292-9. 42 Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen JL, Navea-Tejerina A. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study. Retina 2009;29:530-5. 43 Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008;92:76-80. 44 Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M,et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-405. 45 Takamura Y, Kubo E, Akagi Y. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 2009;116:1151-7. 46 Abu El-Asrar AM, Al-Mezaine HS, Ola MS. Changing paradigms in the treatment of diabetic retinopathy. Curr Opin Ophthalmol 2009;20:532-8. 47 Boscia F. Current approaches to the management of diabetic retinopathy and diabetic macular oedema. Drugs 2010;70:2171-200. 48 Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol 2009;20:166-74. 49 Fard MA, Yazdanei AA, Malihi M. Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: prospective randomized study. Eur J Ophthalmol 2011;21:276-81. 50 Guthoff R, Schrader W, Hennemann K, Meigen T, Gobel W. Prognostic factors for visual outcome after intravitreal drug therapy for chronic diabetic macular oedema. Klinische Monatsblatter fur Augenheilkunde 2011;228:468-72. 51 Hernandez-Da Mota SE, Chacon-Lara A, Hernandez-Vazquez E. Use of triamcinolone and bevacizumab in 25G phaco-vitrectomy surgery for the treatment of cataract and diabetic macular edema. Archivos de la Sociedad Espanola de Oftalmologia 2008;83:293-300. 52 Karim R, Tang B. Use of antivascular endothelial growth factor for diabetic macular edema. Clin Ophthalmol 2010;4:493-517. 53 Kubicka-Trzaska A. Intravitreal ranibizumab in diabetic macular edema. Klinika Oczna 2010;112:333-6. 54 Meyer CH. Current treatment approaches in diabetic macular edema. Ophthalmologica 2007;221:118-31. 55 Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. J Am Med Assoc 2007;298:902-16. 56 Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J,et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-9. 57 Ozkiris A. Pattern electroretinogram changes after intravitreal bevacizumab injection for diabetic macular edema. Documenta Ophthalmologica 2010;120:243-50. 58 Parravano M, Menchini F, Virgili G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2009;4:CD007419. 59 Schwartz SG, Flynn J, Scott IU. Emerging therapies for diabetic macular edema. Expert Rev Ophthalmol 2009;4:163-71. 60 Schwartz SG, Flynn J, Scott IU. Pharmacotherapy for diabetic retinopathy. Expert Opin Pharmacother 2009;10:1123-31. 61 Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP,et al. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina 2008;28:36-40. 62 Waisbourd M, Goldstein M, Loewenstein A. Treatment of diabetic retinopathy with anti-VEGF drugs. Acta Opthalmologica 2011;89:203-7. 63 Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D’Amico R, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134. 64 Song F, Xiong T, Parekh-Bhurke S, Loke YK, Sutton AJ, Eastwood AJ, et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ 2011;343:d4909. 65 Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9. 66 Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol 2011;59:191-6. 67 The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908. 68 Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN Randomized Trial. Ophthalmology 2012;119:1399-411. 69 Campbell RJ, Gill SS, Bronskill SE, Paterson JM, Whitehead M, Bell CM. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 2012;345:e4203. 70 Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009;29:313-8. 71 Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-95. 72 Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;33:S26-34. 73 Lanzetta P, Burian G, Weichselberger A, Hashad Y. Safety profiles of diabetic versus non-diabetic AMD patients in randomized controlled clinical studies with ranibizumab. Invest Ophthalmol Vis Sci 2010;51:91. 74 National Institute for Health and Clinical Excellence. Macular oedema (diabetic)—ranibizumab: appraisal consultation document. 2011. http://guidance.nice.org. uk/TA/Wave23/30/Consultation/DraftGuidance. 75 General Medical Council. Good medical practice. 2006. www.gmc-uk.org/guidance/good_ medical_practice.asp. 76 Cummins E, Lois N, Waugh N. ERG comments on the Novartis responses to the ACD on ranibizumab for diabetic macular oedema. 2011. www.nice.org.uk/nicemedia/live/ 13125/55338/55338.pdf.
URI:	http://wrap.warwick.ac.uk/id/eprint/49885

Request changes to a record

Actions (login required)

View Item